about
MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signalingGenomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention.Targeting the RB-E2F pathway in breast cancerExploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy CombinationA DERL3-associated defect in the degradation of SLC2A1 mediates the Warburg effectInactivating CUX1 mutations promote tumorigenesisMutational signatures of ionizing radiation in second malignanciesInduction of stable drug resistance in human breast cancer cells using a combinatorial zinc finger transcription factor libraryMachine learning prediction of cancer cell sensitivity to drugs based on genomic and chemical propertiesCombinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing's SarcomaA chromatin-mediated reversible drug-tolerant state in cancer cell subpopulationsIntegration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer.Precision oncology for acute myeloid leukemia using a knowledge bank approach.Recurrent PTPRB and PLCG1 mutations in angiosarcoma.Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic CholangiocarcinomaRecurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma.Prognostic significance of TRAIL signaling molecules in stage II and III colorectal cancer.A structure-guided approach to creating covalent FGFR inhibitorsExploiting genetic complexity in cancer to improve therapeutic strategiesGenomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells.A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia.Clinical significance of prognostic and predictive markers in colorectal cancer.Predictive markers for colorectal cancer: current status and future prospects.Origins and functional consequences of somatic mitochondrial DNA mutations in human cancerMobile DNA in cancer. Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes.Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue.The evolutionary history of lethal metastatic prostate cancer.Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells.Potent organo-osmium compound shifts metabolism in epithelial ovarian cancer cells.Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.LIM kinase inhibitors disrupt mitotic microtubule organization and impair tumor cell proliferation.VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancerTargeting MYCN in neuroblastoma by BET bromodomain inhibitionBRAF(V600E) Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived XenograftsA landscape of pharmacogenomic interactions in cancer.Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFRSunitinib prolongs survival in genetically engineered mouse models of multistep lung carcinogenesisLogic models to predict continuous outputs based on binary inputs with an application to personalized cancer therapy.
P50
Q24304423-954E77B7-B949-4E38-AC8C-44487D66E6C1Q27851431-2C4A2851-7343-4E91-8AE5-34B90F0A7BB3Q27852431-9C56111B-512E-4B97-A6A6-A7CE8CC05B54Q28069626-58D91FA3-FEB2-4A09-B9D7-8339A5890C43Q28118450-6028BE33-69D4-4DCE-A3F7-58F54B5D0529Q28237387-D4ECA391-6349-42A1-9401-4FAFC8BA3503Q28303563-54721663-8BB6-4CA7-A25B-018996A83E6DQ28389573-83A907BB-CE9D-4932-AF30-C79678E445A7Q28479198-BE7DECD5-5121-4272-965B-C2C83E320DD0Q28487333-072A41B6-8395-43C2-BCD9-EAD349A6A26FQ28550512-77AD0729-CC63-4EE2-8C91-3746EDC54644Q29614275-8A777560-7365-4C78-8937-23F77470D82FQ31034941-C4CC4B86-A79E-43BB-B55E-5C369BF191B4Q33458896-B2833597-F459-45AC-B1A2-326A42026137Q33657848-29DF2A7D-CD2C-4EE6-A567-B8FDE0AB4176Q33763540-F5CD1F34-4697-4001-8BD0-9461B3526DE6Q33850534-B6120E39-958A-4FD8-8CD1-07623AD3E10BQ33959522-B7CE515E-D2AD-49DB-810B-05A40502A065Q34061522-03ABBDB3-8CF1-4C8E-900F-96541DCFB175Q34255055-320519C9-A8E6-4CD3-A2A1-1C1E8712D472Q34313686-DF5764B7-7A4D-4E5A-BC1B-736B721FB390Q34543038-2B76939D-B474-46EC-A994-112328551D50Q34798558-C74A553A-E551-4D11-A8A6-414A590E01D2Q35079181-D5811AE0-9D21-4EFD-BCB4-E996F2D8CAFEQ35212322-17996C1A-2709-4D95-8AB1-3065037363C1Q35234637-10CBD3FE-96AB-4F78-BEDD-F88342794881Q35235374-80FD80E3-0C06-4DAC-811B-B0DE46F02116Q35548366-40FF7181-F3E2-43F7-81AE-BF0224A5AE0BQ35596369-C3C3C13C-FB08-490E-9949-309E880F74D4Q35664110-C94D0B45-0F43-4F1D-9514-08CDC6D0760EQ35895492-6AC7A743-74FF-4C0A-91F0-B746409E9162Q36288956-787F14B5-232B-4F1A-A434-E7D559C2EE1DQ36629339-C08F2667-CEE0-46EF-9EAC-D4F00C73A430Q36656352-B0A8FB9A-CF47-4C95-8BFA-6C6FBC9B5C0BQ36903802-7AE3A2FC-9AEF-41BE-910E-5BD9760BFFD9Q37056708-F5AAE34C-929C-4825-8B42-BCD54CC0DE04Q37140236-2F1873EB-5020-471A-8A5A-C39BCF4D7CA2Q37142504-BABAE2B0-AF4B-4238-BABC-C5CBF9995F8BQ37226817-6E0F5D6D-D214-40C3-A581-699C266EED7DQ37430970-8588E100-75AC-49EA-8C83-910580F42D76
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Ultan McDermott
@ast
Ultan McDermott
@en
Ultan McDermott
@es
Ultan McDermott
@nl
Ultan McDermott
@sl
type
label
Ultan McDermott
@ast
Ultan McDermott
@en
Ultan McDermott
@es
Ultan McDermott
@nl
Ultan McDermott
@sl
altLabel
McDermott U
@en
prefLabel
Ultan McDermott
@ast
Ultan McDermott
@en
Ultan McDermott
@es
Ultan McDermott
@nl
Ultan McDermott
@sl
P106
P21
P31
P496
0000-0001-9032-4700